Clinical Trial Billing in 2026

Routine Costs vs Research Costs, the Medicare Coverage Analysis and NCT Reporting

By Team Rcmaxis  ·  October 21, 2026  ·  12 min read

In January 2024, a Florida research hospital agreed to pay more than $19.5 million to resolve allegations of improperly billing clinical trial costs, a case it self-disclosed before the government came looking. That number is a useful anchor for anyone who thinks clinical trial billing is a niche coding problem rather than a real compliance exposure: the mistake wasn't exotic, it was billing something to Medicare that the trial sponsor should have paid for instead.

Every research-active practice runs the same risk on a smaller scale. A single clinical trial can generate dozens of line items per visit, some of which are routine care Medicare has always paid for, and some of which exist purely because the protocol asked for them. Mix the two up on a claim, even once, and you've billed a federal payer for something it was never supposed to cover.

Here's how the routine-cost-vs-research-cost split actually works, what the Medicare Coverage Analysis has to establish before you bill a single claim, how NCT reporting and the Q-modifiers work, and what that $19.5 million case should tell you about where to look first.

Routine Costs vs Research Costs: The Split That Decides Who Pays

Medicare's National Coverage Determination 310.1 pays for the routine costs of a qualifying clinical trial, meaning the items and services a patient would have received anyway as part of standard medical care for their condition, whether or not they were in the trial. It also covers reasonable and necessary care for complications that arise from trial participation itself.

Research costs are everything that exists only because the protocol called for it: an extra set of labs the standard of care wouldn't order, additional imaging on a schedule the trial dictates rather than clinical need, and almost always the investigational drug or device itself. Those costs belong to the trial sponsor, not to Medicare or any other payer, and billing them to a payer instead is the single most common, and most expensive, mistake in this space.

The Medicare Coverage Analysis: What It Has to Establish

A Medicare Coverage Analysis (MCA) is the document that does two jobs before billing ever starts. First, it determines whether the trial itself qualifies under NCD 310.1, generally requiring that the trial fall within a Medicare benefit category, have a therapeutic intent, enroll patients with the diagnosed disease rather than healthy volunteers for a therapeutic study, and not be designed solely to test toxicity or disease mechanism. Trials can also qualify by deeming criteria, such as government funding or sponsorship under an active IND application or a qualifying IND exemption.

Second, once a trial qualifies, the MCA goes through the protocol's entire schedule of events and assigns a billing determination, routine cost, research cost, or complication of participation, to every single item and service. That assignment is what tells your coding team which claims lines go to the payer and which get invoiced to the sponsor's trial budget.

Skip this step, or do it loosely, and you're guessing on every claim the trial generates for its entire enrollment period. That's not a one-time risk; it's a recurring one that multiplies with every patient visit until someone catches it.

NCT Reporting, Q1/Q0 Modifiers and Condition Code 30

Once a trial qualifies and its MCA is complete, every claim for routine costs tied to that trial has to carry specific identifiers so the payer's system recognizes it as trial-related rather than standard care. The claim needs the trial's National Clinical Trial (NCT) registration number, HCPCS modifier Q1 for a routine service furnished in the course of a qualifying trial, or Q0 for an investigational item or service, and secondary diagnosis code Z00.6.

Routine costs for a non-qualifying trial get billed without any of these identifiers; they're simply standard claims, because the trial itself never earned coverage under NCD 310.1 in the first place. That distinction, qualifying vs non-qualifying, has to be settled and documented before you decide whether to use these codes at all.

Compliance Exposure: What the $19.5 Million Case Should Tell You

The Florida case resolved in January 2024 is worth studying precisely because it was self-disclosed. The hospital found its own billing problem, voluntarily reported it, and still ended up paying over $19.5 million, with the settlement coordinated through the Department of Justice's Civil Division. HHS-OIG's public statement on the matter made the standard explicit: providers are accountable for billing outside the rules that govern clinical trial reimbursement, self-disclosure doesn't erase the liability, it just changes how the resolution gets negotiated.

Sponsors carry exposure here too, not just sites. Compliance guidance for research organizations warns that a sponsor can face liability for aiding or abetting a false claim when a site under its trial improperly bills a payer, with the same civil and criminal penalty structure, including treble damages under the False Claims Act, that applies to the billing party itself. That's a reason for sponsors to care about a site's MCA quality, not just its enrollment numbers.

Build the Clinical Trial Billing Workflow

Research billing can't live inside your regular claims team's normal workflow without a dedicated checkpoint. Build a separate review step for every trial-related claim: confirm the MCA determination for each line item, confirm the NCT number and modifier are correctly applied, and confirm the claim is going to the right payer, Medicare, commercial insurance, or the trial sponsor's budget, before it goes out the door.

Assign ownership of the MCA to someone who reviews protocol amendments as part of their job, not as an afterthought discovered during a routine audit. Keep a live list of every active trial, its qualifying status, and the date its MCA was last reviewed, so nothing drifts out of date silently.

• Route every trial claim through a dedicated review step. Never let trial billing default into the standard claims workflow.
• Track MCA review dates per trial. A protocol amendment without a corresponding MCA update is a live risk.
• Verify NCT number and Q-modifier accuracy before submission. These fields are exactly what a payer's system checks first.
• Build a self-disclosure process now. Knowing the steps before you need them is the difference between a fast resolution and a slow one.

Our guide to medical necessity documentation covers the broader chart-note standard that supports any billing determination, and our medical billing compliance guide walks through the False Claims Act exposure that applies well beyond research billing specifically.

Frequently Asked Questions About Clinical Trial Billing

What is a Medicare Coverage Analysis for a clinical trial?

A Medicare Coverage Analysis is the document that reviews a clinical trial's protocol line by line and determines two things: whether the trial itself qualifies under NCD 310.1, and which specific items and services in the protocol are routine costs Medicare can pay versus research costs the sponsor has to cover. It has to be completed before billing starts, since every claim's coding depends on the determination it makes.

What is the NCT number and when does it have to go on a claim?

The NCT number is the clinical trial's national identifier from its registration. For a qualifying trial's claims, Medicare requires the NCT number to be reported alongside HCPCS modifier Q1 (for a routine service in a qualifying trial) or Q0 (for an investigational item or service) and secondary diagnosis code Z00.6. On institutional claims, this is flagged with condition code 30.

What's the difference between routine costs and research costs in a clinical trial?

Routine costs are the items and services a qualifying trial's patient would have received anyway as part of standard medical care, which Medicare can pay for under NCD 310.1. Research costs are the items and services performed only because of the protocol, extra scans, extra lab draws, the investigational drug or device itself, which the trial sponsor has to fund. Billing a research cost to Medicare instead of the sponsor is the single most common clinical trial billing error.

What happened in the recent clinical trial billing enforcement case?

In January 2024, a Florida research hospital agreed to pay more than $19.5 million to resolve allegations of improper billing for clinical trial costs, after self-disclosing the issue. The settlement was coordinated with the Department of Justice's Civil Division, and HHS-OIG stated that providers will be held accountable for billing outside the rules that govern clinical trial reimbursement.